Last reviewed · How we verify
CCX-354-C
CCX-354-C is a C-C chemokine receptor 4 (CCR4) antagonist that blocks immune cell recruitment to reduce inflammatory responses.
CCX-354-C is a C-C chemokine receptor 4 (CCR4) antagonist that blocks immune cell recruitment to reduce inflammatory responses. Used for Inflammatory and autoimmune conditions (specific indication under investigation).
At a glance
| Generic name | CCX-354-C |
|---|---|
| Sponsor | Amgen |
| Drug class | CCR4 antagonist |
| Target | CCR4 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
CCR4 is expressed on T cells and other immune cells involved in inflammatory and allergic responses. By antagonizing CCR4, CCX-354-C prevents the migration of these cells to inflamed tissues, thereby reducing inflammation. This mechanism is being explored for autoimmune and inflammatory conditions.
Approved indications
- Inflammatory and autoimmune conditions (specific indication under investigation)
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy (PHASE2)
- Study to Evaluate Safety and Efficacy of CCX 354-C in Subjects With Rheumatoid Arthritis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |